Trial Profile
A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Interleukin-12
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 1 Jan 2018 to 7 Mar 2025.
- 31 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research